$HEPA News

Last published 8mo ago

8mo agoHEPAHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaGlobeNewswireNext-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests
1y agoHEPAHepion Pharmaceuticals Successfully Completes Application to the OTCQBGlobeNewswireMORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease,
1y agoHEPAHepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqGlobeNewswireMORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"),
1y agoHEPAHepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCCGlobeNewswireMORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"),
1y agoHEPAHepion Pharmaceuticals Announces Reverse Stock SplitGlobeNewswireShares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company
1y agoHEPAHepion Pharmaceuticals Announces $9.0 Million Public OfferingGlobeNewswireEDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"),
1y agoHEPAHepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.GlobeNewswireEDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) (the "Company" or "Hepion"), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic
1y agoHEPAPharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study GroupGlobeNewswirePooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson's disease (PD) support P2B001 as a first line, once-daily treatment choice for early PD KIRYAT ONO,
1y agoHEPAHepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two BGlobeNewswireTransaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease Hepion's Board Unanimously Recommends Shareholders Approve the Merger Following
2y agoHEPAPharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed MergerGlobeNewswireKIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ("Pharma Two B"), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the
2y agoHEPAPharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed MergerGlobeNewswireKIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. ("Pharma Two B"), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the
2y agoHEPAPharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private PlacementGlobeNewswirePharma Two B Ltd. ("Pharma Two B") has entered into a merger agreement with Hepion Pharmaceuticals, Inc. ("Hepion") (NASDAQ:HEPA)Immediately upon completion of the merger, current Pharma Two B equity-holders will own
2y agoHEPAHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialGlobeNewswireEDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"),
2y agoHEPAHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellGlobeNewswireEDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic
2y agoHEPAHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsGlobeNewswireEDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the
2y agoHEPAHepion Pharmaceuticals to Present at NASH-TAG 2024GlobeNewswireEDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
2y agoHEPAHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesGlobeNewswireRestructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account current market
2y agoHEPAHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitGlobeNewswireEDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
2y agoHEPAHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseGlobeNewswire- Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease biomarkers and HepQuant Duo liver function test - "These
3y agoHEPAHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of RencofilstatGlobeNewswireEDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelGlobeNewswireEDISON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesGlobeNewswireEDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the
3y agoHEPAHepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceGlobeNewswireEDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPANew Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals' Rencofilstat in Cancer Screening ProgramGlobeNewswire- 850 cancer cell lines screened in Broad Institute's PRISM lab - - Rencofilstat active on 220 cancer cell lines spanning 86% of cancer types – EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals,
3y agoHEPAHepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerGlobeNewswire- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hepion
3y agoHEPARencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisGlobeNewswire– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib –
3y agoHEPAHepion Pharmaceuticals Announces Management ChangesGlobeNewswireEDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-assisted therapeutic drug development
3y agoHEPAHepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023GlobeNewswire- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for
3y agoHEPAHepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b 'ASCEND-NASH' Trial of RencofilstatGlobeNewswireEDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesGlobeNewswireEDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence ("AI")-assisted therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersGlobeNewswire- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat's direct antifibrotic mode of action; increases confidence for reductions in
3y agoHEPAHepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 'ALTITUDE-NASH' Liver Function Trial of RencofilstatGlobeNewswireEDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals, Inc. Announces Reverse Stock SplitGlobeNewswireEDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023GlobeNewswireEDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLsGlobeNewswireEDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug DevelopmentGlobeNewswireEDISON, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 NASH Clinical Program with Rencofilstat at 6th Global NASH CongressGlobeNewswireEDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAEPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion's Patent PortfolioGlobeNewswire– Patent Covers 38 European Countries – – Rencofilstat's Exclusivity May Extend into 2048 – EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
3y agoHEPASingle Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects - NCT05737433ClinicalTrials.govTo determine the mass balance recovery after a single oral dose of [14C]-rencofilstat
3y agoHEPAHepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023GlobeNewswireEDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAAnti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma StudiesGlobeNewswire- Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib - EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a
3y agoHEPAPresentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome InhibitorsGlobeNewswireEDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive FundingGlobeNewswireEDISON, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023GlobeNewswireEDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals, Inc. Granted 180-day Extension by Nasdaq to Meet the Minimum Bid Price RequirementsGlobeNewswireEDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
3y agoHEPAHepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'ALTITUDE-NASH' Liver Function TrialGlobeNewswire– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test – – Hepion, Summit Clinical Research, and HepQuant Align to Deliver Rencofilstat's Hepatic Function and NASH Biomarker
4y agoHEPAHepion Pharmaceuticals to Present Rencofilstat's Poly-Indication Potential at the 6th Annual Antifibrotic Drug Development SummitGlobeNewswireEDISON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
4y agoHEPAHepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewswireEDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
4y agoHEPAHepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting® 2022GlobeNewswireEDISON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for
4y agoHEPAHepion Pharmaceuticals Announces Publication of Phase 2a 'AMBITION' Clinical Trial ResultsGlobeNewswire- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic effects with longer treatment duration - - Enrollment initiated in Phase 2b